Citations

Showing 10 of 108152 citations.

The Medical Physicist in the balance
Herman, Michael , Herman, Michael G.

Mayo Clinic

Journal of Applied Clinical Medical Physics | June 24, 2019 | Volume: 20 | Issue: 7 | Pages: 4-6

10.1002/acm2.12669 | PMID 31231922 Get It

SMART goals setting and biometric changes in obese adults with multimorbidity: Secondary analysis of a randomized controlled trial
Takahashi, Paul Y. , Quigg, Stephanie, Croghan, Ivana T. , Schroeder, Darrell R. , Ebbert, Jon O. , Quigg, Stephanie M, Takahashi, Paul , Schroeder, Darrell

Mayo Clinic

SAGE Open Medicine | June 24, 2019 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/2050312119858042 | PMID 31258905 Get It

Objectives: Clinicians recommend diet and exercise for overweight/obese patients. We conducted a secondary analysis of a randomized controlled clinical trial evaluating goal setting and pedometer use versus usual care on weight, waist circumference, and blood pressure of patients with multiple chronic conditions. Methods: In this trial, we recruited and randomized patients over 18 years with multiple chronic conditions. There were two groups with an immediate intervention group who received behavioral coaching and a pedometer versus a delayed control who received the intervention after 2 months. We evaluated body weight, waist circumference, and blood pressure as outcomes. We used analysis of covariance to evaluate differences between the intervention and the control groups. Results: Of 130 patients, mean age was 63.4 years (SD, 17.3). At 2 months, intervention participants lost 0.2 kg versus a 0.1-kg gain in the control participants ( P = .44). The immediate intervention group had significantly smaller waist circumference change at 2-month follow-up compared to control at −1.6 cm (95% confidence interval = −3.1 to −0.1), which was driven by an increase in waist circumference in the delayed control group. No difference in systolic blood pressure was observed. Discussion: We observed no difference in weight or blood pressure between the groups with obesity and multiple chronic conditions.
HepaticYAP1-TFE3Rearranged Epithelioid Hemangioendothelioma
Lotfalla, Mira , Folpe, Andrew L. , Fritchie, Karen , Galliano, Gretchen G., Halling, Kevin C. , Mounajjed, Taofic, Torres‐Mora, Jorge , Graham, Rondell P. , Lotfalla, Mira M , Fritchie, Karen J. , Torres-Mora, Jorge, Graham, Rondell P , Greipp, Patricia T. , Galliano, Gretchen E.

Mayo Clinic

Case Reports in Gastrointestinal Medicine | June 23, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-5

10.1155/2019/7530845 | PMID 31341686 Get It

Epithelioid hemangioendothelioma (EHE) is an uncommon low-grade malignant vascular tumor that may arise in soft tissue/bone or visceral sites such as the liver and lung. As this tumor exhibits epithelioid morphology, it frequently causes diagnostic confusion with other epithelioid vascular neoplasms as well as carcinoma. While 90% of classic EHE are driven by aWWTR1-CAMTA1fusion gene, a histologically distinctive subset of EHE has been recently shown to harbor a different fusion gene,YAP1-TFE3. This variant is likely underrecognized given its rarity and only recent description. Notably, EHE frequently involves the liver but only one case of hepaticYAP1-TFE3rearranged EHE has been reported to date. We present the second case ofYAP1-TFE3rearranged EHE affecting a 65-year-old woman and presenting as multiple liver masses, with characterization of the fusion gene at the transcriptomic and genomic levels. There are several educational points noted from this case.YAP1-TFE3rearranged EHE shows distinctly vasoformative foci, unlike classic EHE and mimicking angiosarcoma or epithelioid hemangioma. The tumors cells show a histiocytoid appearance with voluminous cytoplasm, similar to otherTFE3-rearranged tumors. Finally, in the liver, this tumor may in part mimic focal nodular hyperplasia of the liver which is an underrecognized diagnostic pitfall. This report highlights the key diagnostic and genetic features of this newly recognized variant of hepatic EHE to aid pathologists in appropriately classifying these tumors.
The Flower Petal Training System in Microsurgery
Volovici, Victor , Dammers, Rúben , Lawton, Michael T., Dirven, Clemens M.F. , Zamfirescu, Dragoş, Volovici, Victor , Lawton, Michael T. , Ketelaar, Tijs , Lanzino, Giuseppe

Mayo Clinic

Annals of Plastic Surgery | June 22, 2019 | Volume: 83 | Issue: 6 | Pages: 697-701

10.1097/sap.0000000000001914 | PMID 31232823 Get It

Introduction Despite hundreds of training models for microsurgery being available in the literature, very few of them are scientifically validated. We chose to validate our low-fidelity training model on flower petals by comparing it head-to-head with a moderate fidelity training model, the anastomosis on chicken leg femoral artery. Materials and methods A total of 16 participants of different levels of expertise were randomized into 2 groups, 1 training on flower petals and 1 on chicken leg femoral arteries. The groups were evaluated on performing a rat femoral artery anastomosis using the validated Stanford Microsurgical Assessment (SMaRT) Scale. The Mann-Whitney U test was used to check for statistically significant differences between the groups. The flower petal sutures were also evaluated and Pearson correlation was used to check for associations between better petal anastomosis scores and better final SMaRT results. Results After 6 weeks of flower petal training, microsurgical trainees had significantly better overall SMaRT scores than trainees using chicken leg training, better fine tissue feeling, and better scores in knot tying. The anastomosis times for the rat femoral arteries did not differ between the 2 groups. Good scores for flower petals strongly correlated with a better SMaRT score for the anastomosis. The number of rats used in training reduced after the implementation of this model in continuous training. Conclusions The flower petal technique, despite being a low-fidelity model, shows superiority in developing fine tissue feeling and improved knot tying in microsurgery beginners and intermediate level practitioners adding this training model to their program. Further research needs to establish if the improvements also apply to already seasoned microsurgeons and whether the petal score has predictive value for future clinical application.
Eyelid Melanoma in the United States: A National Cancer Database Analysis
Oliver, Jeremie D. , Huayllani, María T. , Restrepo, David J. , Spaulding, Aaron , Gabriel, Emmanuel , Rinker, Brian, Forte, Antonio J. , Forte, Antonio Jorge , Spaulding, Aaron , Oliver, Jeremie D , Gabriel, Emmanuel M , Boczar, Daniel , Sisti, Andrea , Bagaria, Sanjay P.

Mayo Clinic

Journal of Craniofacial Surgery | June 22, 2019 | Volume: 30 | Issue: 8 | Pages: 2412-2415

10.1097/scs.0000000000005673 | PMID 31233000 Get It

Background: Eyelid melanoma (EM) is a rare condition that accounts for <1% of all cutaneous melanomas. In this analysis, patients diagnosed with EM in the United States were compared to those with other melanomas in the head and neck. Methods: The National Cancer Database was used to select patients with head and neck melanoma from 2004 to 2015. Results: A total of 137,233 patients met the criteria of the study. Among them, 2694 were diagnosed with EM (2%) and 134,539 in other head and neck locations (98%). Regarding the patients with EM, the mean age was 68.56 years (standard deviation 14.04). A greater number of them were treated in Academic/Research Programs (53.6%), insured by Medicare (55.7%), tumor in situ (52.2%), stage 0 (49%), and without ulceration (75.9%). The mean time to treatment commencement was 18.96 days for EM compared to 14.4 days for other melanoma in the head and neck regions (P < 0.001). There was a greater proportion of EM in female patients (odds ratio [OR] 2.371 [2.191–2.566], P < 0.001), compared to male; age greater than 80 years (OR 1.622 [1.360–1.934], P < 0.001) compared to 0 to 49 years. Moreover, EM was an independent predictor for treatment in Academic/Research Programs (OR 1.258 [1.160–1.365], P < 0.001) and diagnosis at autopsy (OR 1.414 [1.083–1.847], P = 0.011) compared to other melanoma in the head and neck region. Conclusion: These novel findings have the potential to guide clinical decision making in head and neck melanoma management.
Genetic Risk Score in Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus
Goodarzi, Mark O. , Nagpal, Tanvi, Greer, Phil J. , Cui, Jinrui, Chen, Yii‐Der I., Pankow, James S. , Rotter, Jerome I. , Alkaade, Samer, Amann, Stephen T. , Baillie, John , Banks, Peter A. , Conwell, Darwin L. , Coté, Gregory A. , Forsmark, Christopher E., Gardner, Timothy B. , Gelrud, Andrés , Guda, Nalini M. , LaRusch, Jessica, Lewis, Michele D. , Money, Mary E. , Muniraj, Thiruvengadam , Romagnuolo, Joseph , Sandhu, Bimaljit S., Sherman, Stuart , Wilcox, C. Mel, Park, Walter G. , Andersen, Dana K. , Hart, Phil A. , Yadav, Dhiraj , Whitcomb, David C. , Whitcomb, David C , Rotter, Jerome I , Pankow, James S , Lewis, Michele D , Nagpal, Tanvi, Guo, Xiuqing , Brand, Randall E. , Papachristou, Georgios I. , Singh, Vikesh K. , Pandol, Stephen J. , Bellin, Melena D.

Mayo Clinic

Clinical and Translational Gastroenterology | June 22, 2019 | Volume: 10 | Issue: 7 | Pages: e00057

10.14309/ctg.0000000000000057 | PMID 31232720 Get It

Introduction: Diabetes mellitus (DM) is a complication of chronic pancreatitis (CP). Whether pancreatogenic diabetes associated with CP-DM represents a discrete pathophysiologic entity from type 2 DM (T2DM) remains uncertain. Addressing this question is needed for development of specific measures to manage CP-DM. We approached this question from a unique standpoint, hypothesizing that if CP-DM and T2DM are separate disorders, they should be genetically distinct. To test this hypothesis, we sought to determine whether a genetic risk score (GRS) based on validated single nucleotide polymorphisms for T2DM could distinguish between groups with CP-DM and T2DM. Methods: We used 60 T2DM single nucleotide polymorphisms to construct a weighted GRS in 1,613 subjects from the North American Pancreatitis Study 2 and 2,685 subjects from the Multi-Ethnic Study of Atherosclerosis, all of European origin. Results: The mean GRS was identical between 321 subjects with CP-DM and 423 subjects with T2DM (66.53 vs 66.42, P = 0.95), and the GRS of both diabetic groups was significantly higher than that of nondiabetic controls (n = 3,554, P < 0.0001). Exploratory analyses attempting to enrich the CP-DM group for pancreatogenic diabetes, such as eliminating diabetes diagnosed before CP, requiring pancreas-specific comorbidities, or removing those with a family history of diabetes, did not improve the ability of the GRS to distinguish between CP-DM and T2DM. Discussion: Recognizing that we lacked a gold standard to define CP-DM, our study suggests that CP-DM may be a subtype of T2DM, a notion that should be tested in future, large prospective studies.
Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data
Reddy, Vivek Y. , Akehurst, R., Gavaghan, Meghan , Amorosi, Stacey L., Holmes, David R. , Reddy, Vivek Y

Mayo Clinic

Journal of the American Heart Association | June 22, 2019 | Volume: 8 | Issue: 13 | Pages: No page available

10.1161/jaha.118.011577 | PMID 31230500 Get It

Background Recent publications reached conflicting conclusions about the cost‐effectiveness of left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, Marlborough, MA) for stroke risk reduction in nonvalvular atrial fibrillation (AF). This analysis sought to assess the cost‐effectiveness of LAAC relative to both warfarin and nonwarfarin oral anticoagulants (NOACs) using pooled, long‐term data from the randomized PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long‐Term Warfarin) trials. Methods and Results A Markov model was constructed from a US payer perspective with a lifetime (20‐year) horizon. LAAC clinical event rates and stroke outcomes were from pooled PROTECT AF and PREVAIL trial 5‐year data. Warfarin and NOAC inputs were derived from published meta‐analyses. The model was populated with a cohort of 10 000 patients, aged 70 years, at moderate stroke and bleeding risk. Sensitivity analyses were performed. LAAC was cost‐effective relative to warfarin by year 7 ($48 674/quality‐adjusted life‐year) and dominant (more effective and less costly) by year 10. LAAC became cost‐effective and dominant compared with NOACs by year 5. Over a lifetime, LAAC provided 0.60 more quality‐adjusted life‐years than warfarin and 0.29 more than NOACs. In sensitivity analyses, LAAC was cost‐effective relative to warfarin and NOACs in 98% and 95% of simulations, respectively. Conclusions Using pooled, 5‐year PROTECT AF and PREVAIL trial data, LAAC proved to be not only cost‐effective, but cost saving relative to warfarin and NOACs. LAAC with the Watchman device is an economically viable stroke risk reduction strategy for patients with AF seeking an alternative to lifelong anticoagulation.
Circulating Tumor DNA and Hepatocellular Carcinoma
Yang, Ju Dong , Liu, Minetta C. , Kisiel, John B. , Yang, Ju Dong

Mayo Clinic

Seminars in Liver Disease | June 21, 2019 | Volume: 39 | Issue: 04 | Pages: 452-462

10.1055/s-0039-1688503 | PMID 31226727 Get It

AbstractThere is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.
Inhaled corticosteroids prescriptions increased in the ED for recurrent asthma exacerbations by automated electronic reminders in the ED
Farmer, Adam D. , Mirea, Lucia , Rank, Matthew A. , Bulloch, Blake, Vaidya, Vinay, Drewek, Rupali , Rank, Matthew, Mirea, Lucia , Carter, Jodi M.

Mayo Clinic

Journal of Asthma | June 21, 2019 | Volume: 57 | Issue: 10 | Pages: 1140-1144

10.1080/02770903.2019.1635152 | PMID 31226000 Get It

Preserving Civility in Vaccine Policy Discourse
Tilburt, Jon C. , Marcuse, Edgar K., Poland, Gregory A.

Mayo Clinic

JAMA | June 21, 2019 | Volume: 322 | Issue: 3 | Pages: 209

10.1001/jama.2019.7445 | PMID 31225856 Get It